Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month.
PhRMA and its member companies appreciate Commissioner Hamburg’s years of dedication to health care innovation that helps America’s patients.
As PhRMA President and CEO John Castellani noted, Commissioner Hamburg made “significant contributions to the thoughtful regulation of medicines, including science as a basis for better regulatory decisions.”
As a medical doctor like Commissioner Hamburg, I appreciate the FDA’s central public health role. Commissioner Hamburg led the agency through multiple health care challenges while working to approve new medicines for America’s patients. More innovative treatments are on the horizon, and, with the support of the FDA, these discoveries will help to improve the lives of people battling some of the most devastating diseases, including cancer and Alzheimer’s.
With this shared goal in mind, PhRMA looks forward to continued collaboration with the FDA and Acting Commissioner Stephen Ostrof to improve the health of patients here and ensure that they have access to the new medicines they need to live long, healthy lives.
Bill Chin, M.D. Dr. Bill Chin is the former chief medical officer of PhRMA and led the Scientific & Regulatory Advocacy department as executive vice president through the fall of 2017.